BTAD—49

Beta Drugs Ltd

PharmaceuticalsVerified

(a) Capital structure and liquidity for Beta Drugs Ltd show no dilution risk, as shares outstanding remain unchanged between basic and diluted shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. (b) Profitability and returns data are not available for Beta Drugs Ltd, and no industry_config preferred metrics or cohort medians can be compared at this time. (c) Segment and geographic exposure details are not disclosed in the available data, and no revenue concentration metrics are provided to assess risk from specific markets or product lines. (d) Growth trajectory data is limited, as no outlook numeric deltas or revenue history are available to project future performance. (e) Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. Dilution risk is currently low, with no adjustments applied to valuation metrics. (f) No recent events, filings, or transcripts are available to inform the company's current strategic or operational direction.

30-day price · BTAD+159.60 (+13.3%)

Low$1055.10High$1664.60Close$1361.60As of12 May, 00:00 UTC

Profile

CompanyBeta Drugs Ltd

TickerBTAD.NS

SectorHealthcare

BusinessPharmaceuticals & Medical Research

Industry groupPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Key takeaways

Beta Drugs Ltd has no dilution risk based on current share structure.
Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.
No profitability or returns data is available for comparison with industry benchmarks.
No segment or geographic exposure details are disclosed, limiting visibility into revenue concentration risks.
No recent events or filings are available to inform strategic or operational direction.
--
**RATIONALES**:
```json

Financial snapshot

PeriodHA-latest

CurrencyINR

Revenue—

Gross profit—

Operating income—

Net income—

R&D—

SG&A—

D&A—

SBC—

Operating cash flow—

CapEx—

Free cash flow—

Total assets—

Total liabilities—

Total equity—

Cash & equivalents—

Long-term debt—

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY-4$1.16B$179.1M$117.2M$128.4M

FY-3$1.84B$354.4M$248.3M$126.5M

FY-2$2.27B$430.3M$307.2M$229.2M

FY-1$2.96B$501.3M$364.4M$346.0M

FY0$3.62B$620.9M$424.2M$226.4M

PeriodGross %Op %Net %FCF %

FY-4————

FY-3————

FY-2————

FY-1————

FY0————

PeriodAssetsEquityCashDebt

FY-4$1.18B$686.1M——

FY-3$1.58B$923.4M——

FY-2$1.98B$1.23B——

FY-1$2.54B$1.57B——

FY0$4.36B$1.97B——

PeriodOCFCapExFCFSBC

FY-4$186.0M-$57.6M$128.4M—

FY-3$296.3M-$194.3M$126.5M—

FY-2$233.8M-$182.1M$229.2M—

FY-1$309.3M-$116.2M$346.0M—

FY0$361.4M-$368.6M$226.4M—

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2$1.00B$159.8M$117.0M—

FQ-1$1.03B$170.7M$122.2M—

FQ0$872.7M$126.0M$85.2M—

PeriodGross %Op %Net %FCF %

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodAssetsEquityCashDebt

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1$4.88B———

FQ0————

PeriodOCFCapExFCFSBC

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book—

Net cash—

Current ratio—

Debt/Equity—

ROA—

ROE—

Cash conversion—

CapEx/Revenue—

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskUnknown

Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).

Industry benchmarks

Activity: Pharmaceuticals · cohort 779 companies

MetricBTADActivity

Op margin—7.7% medp25 -2.4% · p75 15.5%

Net margin—5.9% medp25 -3.8% · p75 12.8%

Gross margin—45.5% medp25 31.1% · p75 62.9%

R&D / revenue—529.2% medp25 465.2% · p75 593.2%

CapEx / revenue—-7.0% medp25 -14.9% · p75 -3.2%

Debt / equity—25.0% medp25 3.8% · p75 63.3%

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod FQ-7 · history via verified-market-data

no public URL

2026-05-13 00:32 UTC#1a72db34

Source: analysis-pipeline (hybrid)Generated: 2026-05-27 13:52 UTCJob: 7b8e3f73